Yin Wei, Liu Wei, Guo Ming, Tang Zhenya, Toruner Gokce, Robinson Melissa, Cheng Joanne, Hu Shimin, Medeiros L Jeffrey, Tang Guilin
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Exp Mol Pathol. 2021 Feb;118:104572. doi: 10.1016/j.yexmp.2020.104572. Epub 2020 Nov 12.
MET amplification has been associated with shorter survival in cancer patients and thought to represent one of two major mechanisms for developing resistance to therapy with EGFR inhibitors. We retrospectively studied 99 patients who had non-small cell lung cancer (NSCLC) and had at least two FISH analyses for MET/CEP7 at different time points during the course of disease. Four (4%) patients showed MET amplification in the initial diagnostic biopsy, and 16 (16%) patients acquired MET amplification in the follow-up biopsy specimens. Acquired MET amplification was highly associated with EGFR inhibitor treatment. Except for EGFR and TP53 mutations, other gene mutations were rare in the patients with MET amplification. Patients with acquired MET amplification showed no significant survival difference comparing to the patients who did not show MET amplification.
MET基因扩增与癌症患者较短的生存期相关，并且被认为是对表皮生长因子受体（EGFR）抑制剂治疗产生耐药性的两种主要机制之一。我们回顾性研究了99例非小细胞肺癌（NSCLC）患者，这些患者在疾病过程中的不同时间点至少进行了两次MET/CEP7荧光原位杂交（FISH）分析。4例（4%）患者在初次诊断活检时显示MET基因扩增，16例（16%）患者在后续活检标本中出现MET基因扩增。获得性MET基因扩增与EGFR抑制剂治疗高度相关。除EGFR和TP53基因突变外，MET基因扩增患者中其他基因突变很少见。获得性MET基因扩增患者与未出现MET基因扩增的患者相比，生存期无显著差异。
